

Published in final edited form as:

*Nat Genet.* ; 44(6): 670–675. doi:10.1038/ng.2261.

## Meta-analysis identifies six new susceptibility loci for atrial fibrillation

Patrick T Ellinor<sup>1,2,3,4,74</sup>, Kathryn L Lunetta<sup>5,6,74</sup>, Christine M Albert<sup>4,7,8,74</sup>, Nicole L Glazer<sup>9,74</sup>, Marylyn D Ritchie<sup>10,11,74</sup>, Albert V Smith<sup>12,74</sup>, Dan E Arking<sup>13,74</sup>, Martina Müller-Nurasyid<sup>14,15,16,74</sup>, Bouwe P Krijthe<sup>17,74</sup>, Steven A Lubitz<sup>1,7,74</sup>, Joshua C Bis<sup>9,74</sup>, Mina K Chung<sup>18,19,74</sup>, Marcus Dörr<sup>20,74</sup>, Kouichi Ozaki<sup>21,74</sup>, Jason D Roberts<sup>22</sup>, J Gustav Smith<sup>23,24</sup>, Arne Pfeufer<sup>25,26</sup>, Moritz F Sinner<sup>1,6,14</sup>, Kurt Lohman<sup>27</sup>, Jingzhong Ding<sup>28</sup>, Nicholas L Smith<sup>29,30,31</sup>, Jonathan D Smith<sup>18,32</sup>, Michiel Rienstra<sup>1,33</sup>, Kenneth M Rice<sup>34</sup>, David R Van Wagener<sup>18,19</sup>, Jared W Magnani<sup>6,35</sup>, Reza Wakili<sup>14</sup>, Sebastian Clauss<sup>14</sup>, Jerome I Rotter<sup>36</sup>, Gerhard Steinbeck<sup>14</sup>, Lenore J Launer<sup>37</sup>, Robert W Davies<sup>38</sup>, Matthew Borkovich<sup>22</sup>, Tamara B Harris<sup>37</sup>, Honghuang Lin<sup>35</sup>, Uwe Völker<sup>39</sup>, Henry Völzke<sup>40</sup>, David J Milan<sup>1,2</sup>, Albert Hofman<sup>17,41</sup>, Eric Boerwinkle<sup>42</sup>, Lin Y Chen<sup>43</sup>, Elsayed Z Soliman<sup>44</sup>, Benjamin F Voight<sup>24</sup>, Guo Li<sup>9</sup>, Aravinda Chakravarti<sup>13</sup>, Michiaki Kubo<sup>45</sup>, Usha B Tedrow<sup>4,7,8</sup>, Lynda M Rose<sup>7</sup>, Paul M Ridker<sup>4,7,8</sup>, David Conen<sup>46</sup>, Tatsuhiko Tsunoda<sup>47</sup>, Tetsushi Furukawa<sup>48</sup>, Nona Sotoodehnia<sup>9,49</sup>, Siyan Xu<sup>5,50</sup>, Naoyuki Kamatani<sup>51</sup>, Daniel Levy<sup>6</sup>, Yusuke Nakamura<sup>52</sup>, Babar Parvez<sup>53</sup>, Saagar Mahida<sup>1</sup>, Karen L Furie<sup>4,54</sup>, Jonathan Rosand<sup>3,4,54</sup>, Raafia Muhammad<sup>53</sup>, Bruce M Psaty<sup>9,30,31,55</sup>, Thomas Meitinger<sup>25,26</sup>, Siegfried Perz<sup>56</sup>, H-Erich Wichmann<sup>57,58,59</sup>, Jacqueline C M Witteman<sup>17,60</sup>, W H Linda Kao<sup>60,61</sup>, Sekar Kathiresan<sup>24,62</sup>, Dan M Roden<sup>53,63</sup>, Andre G Uitterlinden<sup>16,41,64</sup>, Fernando Rivadeneira<sup>17,41,64</sup>, Barbara McKnight<sup>34</sup>, Marketa Sjögren<sup>65</sup>, Anne B Newman<sup>66</sup>, Yongmei Liu<sup>67</sup>, Michael H Gollob<sup>22</sup>, Olle Melander<sup>65</sup>, Toshihiro Tanaka<sup>21,75</sup>, Bruno H Ch Stricker<sup>17,41,64,68,69,75</sup>, Stephan B Felix<sup>20,75</sup>, Alvaro Alonso<sup>70,75</sup>, Dawood Darbar<sup>53,75</sup>, John Barnard<sup>71,75</sup>, Daniel I Chasman<sup>4,7,75</sup>, Susan R Heckbert<sup>30,31,75</sup>, Emelia J Benjamin<sup>6,35,50,72,75</sup>, Vilmundur Gudnason<sup>12,75</sup>, and Stefan Kääb<sup>14,73,75</sup>

Correspondence should be addressed to P.T.E. (pellinor@partners.org) or S. Kääb (skaab@medlmu.de).

<sup>74</sup>These authors contributed equally to this work.

<sup>75</sup>These authors jointly directed this work.

*Note: Supplementary information is available in the online version of the paper.*

### AUTHOR CONTRIBUTIONS

Study concept and design was determined by P.T.E., K.L.L., C.M.A., B.P.K., M.K.C., J.D., H.V., A.H., Y.N., D.M.R., A.G.U., A.B.N., Y.L., T. Tanaka, B.H.C.S., S.B.F., D.D., S.R.H., E.J.B., V.G. and S.K. Acquisition of data was performed by P.T.E., C.M.A., N.L.G., J.C.B., M.K.C., M.D., J.D.R., A.P., M.F.S., J.D., N.L.S., J.D.S., R.W., J.I.R., L.J.L., T.B.H., U.V., A.H., E.Z.S., M.K., U.B.T., D.C., T.F., R.M., B.M.P., T.M., S.P., H.-E.W., J.C.M.W., A.G.U., F.R., M.S., A.B.N., Y.L., M.H.G., B.H.C.S., A.A., S.R.H., E.J.B., V.G. and S.K. Analysis and interpretation of data were performed by P.T.E., K.L.L., N.L.G., M.D.R., A.V.S., D.E.A., M.M.-N., B.P.K., S.A.L., J.C.B., M.D., K.O., J.D.R., J.G.S., M.F.S., K.L., J.D., N.L.S., K.M.R., J.I.R., R.D.W., U.V., G.L., T. Tsunoda, N.S., N.K., B.M.P., S.K., D.M.R., B.M., Y.L., M.H.G., D.D., S.R.H. and E.J.B. Drafting of the manuscript was carried out by P.T.E., K.L.L., B.P.K., S.A.L. and S.K. Critical revision of the manuscript for important intellectual content was carried out by C.M.A., N.L.G., A.V.S., D.E.A., B.P.K., J.C.B., M.K.C., M.D., J.G.S., A.P., M.F.S., J.D., N.L.S., J.D.S., M.R., K.M.R., D.R.V.W., J.W.M., R.W., J.I.R., L.J.L., T.B.H., U.V., H.V., D.J.M., A.H., L.Y.C., E.Z.S., G.L., U.B.T., P.M.R., D.C., N.S., S.M., K.L.F., B.M.P., T.M., S.P., J.C.M.W., D.M.R., A.G.U., F.R., B.M., M.S., A.B.N., Y.L., M.H.G., O.M., B.H.C.S., S.B.F., A.A., D.D., D.I.C., S.R.H., E.J.B. and V.G. Statistical analysis was performed by K.L.L., N.L.G., M.D.R., A.V.S., D.E.A., M.M.-N., B.P.K., J.C.B., J.G.S., M.F.S., K.L., J.D., K.M.R., R.W.D., U.V., G.L., L.M.R., Y.L. and D.I.C. Funding was obtained by P.T.E., C.M.A., M.K.C., J.G.S., N.L.S., J.D.S., J.I.R., L.J.L., T.B.H., H.V., A.H., E.B., U.B.T., P.M.R., B.M.P., T.M., H.-E.W., J.C.M.W., D.M.R., A.G.U., Y.L., O.M., B.H.C.S., S.B.F., A.A., D.D., S.R.H., E.J.B., V.G. and S.K. Study supervision was performed by P.T.E., K.L.L., C.M.A., M.K.C., N.L.S., J.I.R., A.H., P.M.R., B.M.P., J.C.M.W., A.G.U., Y.L., B.H.C.S., S.B.F., S.R.H., E.J.B., V.G. and S.K. P.T.E., K.L.L., C.M.A., N.L.G., M.D.R., A.V.S., D.E.A., M.M.-N., B.P.K., N.A.L., J.C.B., M.K.C., M.D., K.O., T. Tanaka, B.H.C.S., S.B.F., A.A., D.D., J.B., D.I.C., S.R.H., V.G., E.J.B. and S. Kääb had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

<sup>1</sup>Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, USA <sup>2</sup>Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, Massachusetts, USA <sup>3</sup>Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA <sup>4</sup>Harvard Medical School, Boston, Massachusetts, USA <sup>5</sup>Department of Biostatistics, School of Public Health, Boston University, Boston, Massachusetts, USA <sup>6</sup>National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA <sup>7</sup>Division of Preventive Medicine, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA <sup>8</sup>Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts, USA <sup>9</sup>Department of Medicine, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA <sup>10</sup>Center for Systems Genomics, Pennsylvania State University, University Park, Pennsylvania, USA <sup>11</sup>Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania, USA <sup>12</sup>Icelandic Heart Association Research Institute, Kopavogur, Iceland <sup>13</sup>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA <sup>14</sup>Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany <sup>15</sup>Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany <sup>16</sup>Institute of Genetic Epidemiology, Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany <sup>17</sup>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands <sup>18</sup>Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA <sup>19</sup>Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA <sup>20</sup>Department of Internal Medicine B, Ernst Moritz Arndt University Greifswald, Greifswald, Germany <sup>21</sup>Laboratory for Cardiovascular Diseases, RIKEN Center for Genomic Medicine, Kanagawa, Japan <sup>22</sup>Arrhythmia Research Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada <sup>23</sup>Department of Cardiology, Lund University, Lund, Sweden <sup>24</sup>Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA <sup>25</sup>Institute of Human Genetics, Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany <sup>26</sup>Institute of Human Genetics, TU München, Klinikum Rechts der Isar, Munich, Germany <sup>27</sup>Department of Biostatistical Sciences, Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA <sup>28</sup>Sticht Center on Aging, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA <sup>29</sup>Seattle Epidemiologic Research and Information Center of the Department of Veterans Affairs Office of Research and Development, Seattle, Washington, USA <sup>30</sup>Group Health Research Institute, Group Health Cooperative, Seattle, Washington, USA <sup>31</sup>Department of Epidemiology, University of Washington, Seattle, Washington, USA <sup>32</sup>Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA <sup>33</sup>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands <sup>34</sup>Department of Biostatistics, University of Washington, Seattle, Washington, USA <sup>35</sup>Cardiology Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA <sup>36</sup>Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA <sup>37</sup>Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, US National Institutes of Health, Bethesda, Maryland, USA <sup>38</sup>Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada <sup>39</sup>Interfaculty Institute for Genetics and Functional Genomics, Ernst Moritz Arndt University Greifswald, Greifswald, Germany <sup>40</sup>Institute for Community Medicine, Ernst Moritz Arndt University Greifswald, Greifswald, Germany <sup>41</sup>Netherlands Consortium for Healthy Aging (NCHA), The Netherlands <sup>42</sup>Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, USA <sup>43</sup>Cardiac Arrhythmia Center, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA <sup>44</sup>Epidemiological Cardiology Research Center (EPICARE), Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA <sup>45</sup>Laboratory for Genotyping Development,

RIKEN Center for Genomic Medicine, Kanagawa, Japan <sup>46</sup>Department of Medicine, University Hospital, Basel, Switzerland <sup>47</sup>Laboratory for Medical Informatics, RIKEN Center for Genomic Medicine, Kanagawa, Japan <sup>48</sup>Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan <sup>49</sup>Division of Cardiology, University of Washington, Seattle, Washington, USA <sup>50</sup>Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, USA <sup>51</sup>Laboratory for Statistical Analysis, RIKEN Center for Genomic Medicine, Kanagawa, Japan <sup>52</sup>Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan <sup>53</sup>Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA <sup>54</sup>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA <sup>55</sup>Department of Health Services, University of Washington, Seattle, Washington, USA <sup>56</sup>Institute for Biological and Medical Imaging, Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany <sup>57</sup>Institute of Epidemiology I, Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany <sup>58</sup>Chair of Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany <sup>59</sup>Klinikum Grosshadern, Munich, Germany <sup>60</sup>Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA <sup>61</sup>The Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland, USA <sup>62</sup>Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA <sup>63</sup>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA <sup>64</sup>Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands <sup>65</sup>Department of Clinical Sciences, Lund University, Malmö, Sweden <sup>66</sup>Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA <sup>67</sup>Department of Epidemiology & Prevention, Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA <sup>68</sup>Inspectorate for Health Care, The Hague, The Netherlands <sup>69</sup>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands <sup>70</sup>Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA <sup>71</sup>Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA <sup>72</sup>Preventive Medicine Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA <sup>73</sup>Munich Heart Alliance, Munich, Germany

## Abstract

Atrial fibrillation is a highly prevalent arrhythmia and a major risk factor for stroke, heart failure and death<sup>1</sup>. We conducted a genome-wide association study (GWAS) in individuals of European ancestry, including 6,707 with and 52,426 without atrial fibrillation. Six new atrial fibrillation susceptibility loci were identified and replicated in an additional sample of individuals of European ancestry, including 5,381 subjects with and 10,030 subjects without atrial fibrillation ( $P < 5 \times 10^{-8}$ ). Four of the loci identified in Europeans were further replicated *in silico* in a GWAS of Japanese individuals, including 843 individuals with and 3,350 individuals without atrial fibrillation. The identified loci implicate candidate genes that encode transcription factors related to cardiopulmonary development, cardiac-expressed ion channels and cell signaling molecules.

---

Genome-wide association studies in individuals of European descent have identified three genomic regions associated with atrial fibrillation on chromosomes 4q25 (*PITX2*)<sup>2–5</sup>, 16q22 (*ZFHX3*)<sup>3,5</sup> and 1q21 (*KCNN3*)<sup>2</sup>. Studies of electrocardiographic traits have also identified a number of loci associated with atrial fibrillation<sup>6,7</sup>. However, despite these findings, much of the heritability of atrial fibrillation remains unexplained, justifying the search for additional genetic variants underlying atrial fibrillation risk<sup>8</sup>. Large-scale meta-analysis of GWAS results is a powerful method to identify additional genetic variation underlying traits

and conditions. We therefore conducted a meta-analysis of multiple well-phenotyped GWAS samples of European ancestry to identify additional atrial fibrillation susceptibility loci.

Six prospective cohort and 10 prevalent study samples contributed to the discovery analysis, which was adjusted for age and sex (Table 1, Online Methods and Supplementary Note). Atrial fibrillation status was systematically ascertained in each sample (Online Methods and Supplementary Note). After application of quality control SNP exclusion criteria in each study (Supplementary Table 1), meta-analysis was performed, applying genomic control to each study. The genomic control inflation factor for the meta-analysis was 1.042 for the full set of SNPs and 1.040 after omitting all SNPs within 500 kb of the association signals that reached genome-wide significance. The quantile-quantile plot of the expected versus observed  $P$ -value distributions for association of the 2,609,549 SNPs analyzed is shown (Supplementary Fig. 1). We identified ten loci that exceeded our preset threshold for genome-wide significance ( $P < 5 \times 10^{-8}$ ) (Fig. 1). The three loci most significantly associated with atrial fibrillation were at previously identified atrial fibrillation susceptibility loci on chromosomes 4q25 in *PITX2* (rs6817105;  $P = 1.8 \times 10^{-74}$ )<sup>4</sup>, 16q22 in *ZFHX3* (rs2106261;  $P = 3.2 \times 10^{-16}$ )<sup>3,5</sup> and 1q21 in *KCNN3* (rs6666258;  $P = 2.0 \times 10^{-14}$ )<sup>2</sup> (Table 2).

Seven new genomic loci were associated with atrial fibrillation with  $P < 5 \times 10^{-8}$  in the discovery stage (Table 2). The most significantly associated SNP in each of the seven new loci was genotyped and tested for association with atrial fibrillation in an additional 3,132 to 5,289 independent individuals with atrial fibrillation and 8,159 to 11,148 referent individuals derived from six studies of individuals of European ancestry (Supplementary Table 2). Six of the loci associated with atrial fibrillation in the discovery stage met our criteria for independent replication. Study-specific replication results are detailed (Supplementary Table 3). The results from meta-analysis of the discovery and replication results are shown (Table 2), as are regional plots (Fig. 2). Recognizing that the genes in closest physical proximity to the associated SNPs are not always the causative genes, we report below the genetic associations in order of statistical significance along with the nearest gene.

The most significant new association in the discovery stage was on chromosome 1q24 (rs3903239; overall  $P = 8.4 \times 10^{-14}$ ) in *PRRX1*, which encodes a homeodomain transcription factor highly expressed in the developing heart, particularly in connective tissue. Biological interaction between *PRRX1* and a related homeobox transcription factor gene, *PRRX2*, results in abnormalities of great vessel development in a mouse knockout model<sup>9</sup>. In a separate *PRRX1* knockout, fetal pulmonary vasculature development was impaired<sup>10</sup>.

A second locus was identified on chromosome 7q31 (rs3807989; overall  $P = 3.6 \times 10^{-12}$ ) in *CAVI*, which encodes caveolin-1, a cellular membrane protein involved in signal transduction. *CAVI* is selectively expressed in the atria<sup>11</sup>, and its knockout has been associated with dilated cardiomyopathy<sup>12</sup>. The *CAVI* protein colocalizes with and negatively regulates the activity of *KCNH2* (ref. 13), a potassium channel involved in cardiac repolarization; the corresponding *KCNH2* gene was found to be associated with atrial fibrillation in a candidate gene association study, although not in our present analysis<sup>14</sup>. The top SNP at the *CAVI* locus identified in the current study, rs3807989, was previously identified in a GWAS of the PR and QRS intervals and related to atrial fibrillation<sup>6,7</sup>. The relationship between other previously reported PR-associated loci and atrial fibrillation are reported (Supplementary Table 4). Of note, significant associations



with atrial fibrillation were observed for SNPs related to the PR interval in *SOX5*, *TBX5*, *SCN5A* and *SCN10A*<sup>6,7</sup>.

The third locus on chromosome 14q23 (rs1152591; overall  $P = 5.8 \times 10^{-13}$ ) was located in an intron of *SYNE2*, which encodes numerous nesprin-2 isoforms, some of which are highly expressed in the heart and skeletal muscle. Nesprin-2 localizes throughout the sarcomere and is involved in maintaining nuclear structural integrity by anchoring the nucleus to the cytoskeleton. In a candidate gene approach, mutations in *SYNE2* were found to segregate in some families with Emery-Dreifuss muscular dystrophy<sup>15</sup>, which is characterized by skeletal muscle atrophy, cardiomyopathy and cardiac conduction defects.

The fourth locus on chromosome 9q22 (rs10821415; overall  $P = 4.2 \times 10^{-11}$ ) was located in an ORF on chromosome 9. Genes at this locus include *FBP1* and *FBP2*, which are important for gluconeogenesis. Autosomal recessive *FBP1* deficiency has been described, but cardiovascular features did not seem to be prominent<sup>16</sup>. Variants at 9q22 have been implicated in the regulation of height, pulmonary function, angiogenesis and attention deficit hyperactivity disorder, although rs10821415 is not in substantial linkage disequilibrium (LD) with any of these SNPs ( $r^2 < 0.30$ ).

A fifth signal was located at 15q24 (rs7164883; overall  $P = 2.8 \times 10^{-17}$ ) in the first intron of *HCN4*. The HCN4 protein is the predominant cardiac hyperpolarization-activated cyclic nucleotide-gated channel and is highly expressed in the sinoatrial node. HCN4 activity underlies the funny current ( $I_f$ ) that governs cardiac pacemaking, and mutations in *HCN4* have been associated with various forms of sinus nodal dysfunction<sup>17,18</sup>.

A sixth locus on chromosome 10q22 (rs10824026; overall  $P = 4.0 \times 10^{-9}$ ) was located 5 kb upstream of *SYNPO2L* and 20 kb upstream of *MYOZ1*. The proteins encoded by *SYNPO2L* and *MYOZ1* are both expressed in skeletal and cardiac muscle, localize to the Z-disc and interact with numerous other proteins. However, the precise role of either gene in cardiovascular physiology is unknown<sup>19,20</sup>. A mouse knockout of *MYOZ1* showed increased calcineurin activity and cardiac hypertrophy in response to pressure overload. However, candidate gene approaches have not supported a prominent role for *MYOZ1* mutations in causing familial dilated cardiomyopathy<sup>21</sup>. Of note, the *SYNPO2L* locus is located within a previously reported atrial fibrillation susceptibility locus identified in a family with autosomal dominant atrial fibrillation<sup>22</sup>.

One other locus was identified in the meta-analysis of atrial fibrillation in the *WNT8A* gene (rs2040862;  $P = 3.2 \times 10^{-8}$ ); however, this association failed to replicate in additional independent cohorts with atrial fibrillation (replication  $P = 0.36$ ; combined  $P = 2.5 \times 10^{-7}$ ).

There was evidence of significant heterogeneity in the discovery meta-analysis at the previously published atrial fibrillation susceptibility signals at 4q25 in *PITX2* and at 16q22 in *ZFHX3* (Table 2). Effect heterogeneity at the *PITX2* locus has already been observed<sup>4,23,24</sup>.

We then sought to determine whether the top SNPs or their proxies at each locus were associated with alterations in gene expression in an expression quantitative trait locus (eQTL) database, the Genotype-Tissue Expression eQTL browser. The top SNP at the *SYNPO2L* locus, rs10824026, is in strong LD with a SNP, rs12570126 ( $R^2 = 0.932$ ), that was found to correlate with the expression of *MYOZ1* and *SYNPO2L* ( $P = 1.5 \times 10^{-6}$ ; data derived from lymphoblastoid cell lines in 270 individuals from the HapMap Consortium)<sup>25</sup>. Furthermore, the top SNP at the *SYNPO2L* locus is in LD with a nonsynonymous SNP in *SYNPO2L*, rs3812629 ( $R^2 = 0.8$ ; encoding the SYNPO2L P707L variant with respect to transcript Q9H987-1), that is predicted to be damaging by both the PolyPhen-2 and the SIFT

algorithms. None of the other identified atrial fibrillation risk SNPs were associated with variations in gene expression in the Genotype-Tissue Expression eQTL browser.

We next examined the generalizability of our findings by examining our results in a separate GWAS of individuals of Japanese ancestry, including 843 subjects with and 3,350 subjects without atrial fibrillation in the Japan BioBank study (Supplementary Fig. 2a,b). Within the Japanese GWAS, only the chromosome 4q25 (*PITX2*) locus exceeded the preset threshold for genome-wide significance (rs2634073; odds ratio (OR) = 1.84, 95% confidence interval (CI) = 1.59–2.13;  $3.7 \times 10^{-17}$ ; Supplementary Figs. 2a and 3 and Supplementary Table 5). At the previously published locus at 16q22 (*ZFHX3*)<sup>3,5</sup>, rs12932445 was associated with atrial fibrillation in participants of Japanese ancestry ( $P = 6.8 \times 10^{-4}$ ). The relationship between atrial fibrillation and variants at the *KCNN3-PMVK* locus on chromosome 1q21 failed to replicate ( $P = 0.17$ ); however, a regional plot of this locus revealed a distinct signal at the rs7514452 SNP—approximately 375 kb away from rs6666258, the top SNP in the European ancestry sample—that was modestly associated with atrial fibrillation in the Japanese sample ( $P = 4.9 \times 10^{-5}$ ;  $R^2 = 0.002$ ). At *PRRX1* and *CAVI*, the top SNPs in the European samples were also associated with atrial fibrillation in Japanese individuals. For the loci near *PRRX1* and *C9orf3*, alternate SNPs in the Japanese cohort were more significantly associated with atrial fibrillation than the top SNP at each locus in Europeans (Supplementary Fig. 3 and Supplementary Table 5).

Our study was subject to a number of limitations. To maximize both the power and the generalizability of our study, we included all available individuals with atrial fibrillation; thus, some individuals had comorbidities, such as systolic dysfunction and hypertension. However, none of the identified risk variants for atrial fibrillation were strongly associated with systolic dysfunction in the EchoGen Consortium<sup>26</sup>, a meta-analysis of echocardiographic data from 5 community-based cohorts consisting of over 12,000 individuals of European descent ( $P$  value  $< 1 \times 10^{-5}$ ). Further, when our replication results were adjusted for hypertension status, the identified variants remained significantly associated with atrial fibrillation (Supplementary Table 3). Ultimately, the development of a comprehensive risk score incorporating clinical, biochemical and genetic marker data will be necessary to clarify the incremental benefit of our findings in clinical care. Our eQTL analyses were limited to data available within the Genotype-Tissue Expression eQTL browser; future eQTL analyses in cardiac tissue may be helpful in identifying a relationship between the SNPs associated with atrial fibrillation risk and gene expression. Finally, we acknowledge that the identified variants may not be causal but may represent causal elements in the same or different molecular pathways; future statistical, bioinformatic and biological analyses investigating potential genetic interactions are warranted. Fine mapping and deep resequencing will be necessary to uncover the genetic architecture accompanying the identified common atrial fibrillation susceptibility signals.

In summary, our GWAS meta-analysis for atrial fibrillation has identified six new susceptibility loci in or near plausible candidate genes involved in pacemaking activity, signal transduction and cardiopulmonary development. Our results show that atrial fibrillation has multiple genetic associations and identifies new targets for biological investigation.

## URLs

BIMBAM, <http://quartus.uchicago.edu/~yguan/bimbam/index.html>; Genotype-Tissue Expression eQTL browser, <http://www.ncbi.nlm.nih.gov/gtex/GTEX2/gtex.cgi>; iControlDB database, <http://www.illumina.com/science/icontroldb.ilmn>; IMPUTE, <https://mathgen.stats.ox.ac.uk/impute/impute.html>; MACH,

<http://www.sph.umich.edu/csg/abecasis/MACH/>; METAL, <http://www.sph.umich.edu/csg/abecasis/metal/index.html>; PolyPhen-2, <http://genetics.bwh.harvard.edu/pph2/>; SIFT, <http://sift.jcvi.org/>; SNAP, <http://www.broadinstitute.org/mpg/snap/ldsearch.php>.

## METHODS

Methods and any associated references are available in the online version of the paper.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


Acknowledgments are contained in the Supplementary Note.

## References


1. Fuster V, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation*. 2006; 114:e257–e354. [PubMed: 16908781]
2. Ellinor PT, et al. Common variants in *KCNN3* are associated with lone atrial fibrillation. *Nat. Genet.* 2010; 42:240–244. [PubMed: 20173747]
3. Benjamin EJ, et al. Variants in *ZFHX3* are associated with atrial fibrillation in individuals of European ancestry. *Nat. Genet.* 2009; 41:879–881. [PubMed: 19597492]
4. Gudbjartsson DF, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. *Nature*. 2007; 448:353–357. [PubMed: 17603472]
5. Gudbjartsson DF, et al. A sequence variant in *ZFHX3* on 16q22 associates with atrial fibrillation and ischemic stroke. *Nat. Genet.* 2009; 41:876–878. [PubMed: 19597491]
6. Pfeufer A, et al. Genome-wide association study of PR interval. *Nat. Genet.* 2010; 42:153–159. [PubMed: 20062060]
7. Holm H, et al. Several common variants modulate heart rate, PR interval and QRS duration. *Nat. Genet.* 2010; 42:117–122. [PubMed: 20062063]
8. Lubitz SA, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. *J. Am. Med. Assoc.* 2010; 304:2263–2269.
9. Bergwerff M, et al. Loss of function of the *Prx1* and *Prx2* homeobox genes alters architecture of the great elastic arteries and ductus arteriosus. *Virchows Arch.* 2000; 436:12–19. [PubMed: 10664157]
10. Ihida-Stansbury K, et al. Paired-related homeobox gene *Prx1* is required for pulmonary vascular development. *Circ. Res.* 2004; 94:1507–1514. [PubMed: 15117820]
11. Volonte D, McTiernan CF, Drab M, Kasper M, Galbiati F. Caveolin-3 form heterooligomeric complexes in atrial cardiac myocytes that are required for doxorubicin-induced apoptosis. *Am. J. Physiol. Heart Circ. Physiol.* 2008; 294:H392–H401. [PubMed: 17982011]
12. Zhao YY, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. *Proc. Natl. Acad. Sci. USA.* 2002; 99:11375–11380. [PubMed: 12177436]
13. Lin J, et al. The regulation of the cardiac potassium channel (HERG) by caveolin-1. *Biochem. Cell Biol.* 2008; 86:405–415. [PubMed: 18923542]
14. Sinner MF, et al. The non-synonymous coding I<sub>Kr</sub>-channel variant *KCNH2-K897T* is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of *KCNH2* (*HERG*). *Eur. Heart J.* 2008; 29:907–914. [PubMed: 18222980]

15. Zhang Q, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. *Hum. Mol. Genet.* 2007; 16:2816–2833. [PubMed: 17761684]
16. Matsuura T, et al. Two newly identified genomic mutations in a Japanese female patient with fructose-1,6-bisphosphatase (FBPase) deficiency. *Mol. Genet. Metab.* 2002; 76:207–210. [PubMed: 12126934]
17. Schulze-Bahr E, et al. Pacemaker channel dysfunction in a patient with sinus node disease. *J. Clin. Invest.* 2003; 111:1537–1545. [PubMed: 12750403]
18. Milanesi R, Baruscotti M, Gneccchi-Ruscione T, DiFrancesco D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. *N. Engl. J. Med.* 2006; 354:151–157. [PubMed: 16407510]
19. Frey N, Olson EN. Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins. *J. Biol. Chem.* 2002; 277:13998–14004. [PubMed: 11842093]
20. Beqqali A, et al. CHAP is a newly identified Z-disc protein essential for heart and skeletal muscle function. *J. Cell Sci.* 2010; 123:1141–1150. [PubMed: 20215401]
21. Arola AM, et al. Mutations in *PDLIM3* and *MYOZ1* encoding myocyte Z line proteins are infrequently found in idiopathic dilated cardiomyopathy. *Mol. Genet. Metab.* 2007; 90:435–440. [PubMed: 17254821]
22. Brugada R, et al. Identification of a genetic locus for familial atrial fibrillation. *N. Engl. J. Med.* 1997; 336:905–911. [PubMed: 9070470]
23. Lubitz SA, et al. Independent susceptibility markers for atrial fibrillation on chromosome 4q25. *Circulation.* 2010; 122:976–984. [PubMed: 20733104]
24. Kääh S, et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. *Eur. Heart J.* 2009; 30:813–819. [PubMed: 19141561]
25. Stranger BE, et al. Population genomics of human gene expression. *Nat. Genet.* 2007; 39:1217–1224. [PubMed: 17873874]
26. Vasan RS, et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. *J. Am. Med. Assoc.* 2009; 302:168–178.
27. Johnson AD, et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics.* 2008; 24:2938–2939. [PubMed: 18974171]





**Figure 1.** Manhattan plot of meta-analysis results for genome-wide association with atrial fibrillation. The  $-\log_{10}(P$  value) is plotted against the physical position of each SNP on each chromosome. The threshold for genome-wide significance,  $P < 5 \times 10^{-8}$ , is indicated by the dashed line. The three previously reported loci for atrial fibrillation are indicated in blue, and the seven new loci that exceeded the genome-wide significance threshold are indicated in orange.



**Figure 2.** Regional plots for seven new atrial fibrillation loci in the discovery sample with  $P < 1 \times 10^{-8}$ . SNPs are plotted by meta-analysis  $P$  value and genomic position (NCBI Build 36). The SNP of interest is labeled. The strength of LD is indicated by red coloring. Estimated recombination rates are shown by the blue peaks, and gene annotations are indicated by dark green arrows. LD and recombination rates are based on the Utah residents of Northern and Western European ancestry (CEU) HapMap cohort (release 22). Plots were prepared using SNAP<sup>27</sup>.

Table 1

## Subject characteristics

Cohort	Cohort type	Participants (n)	AF (n)	Males (%)	Age at DNA collection (mean ± s.d.)	Age at DNA collection (range)	Age of AF onset (mean ± s.d.)	Hypertension n (%)	Body mass index, in kg/m <sup>2</sup> (mean ± s.d.)	Diabetes n (%)	Myocardial infarction n (%)	Heart failure n (%)
Incident AF												
		Overall N										
ARIC	Cohort	8,890	802	4,181 (47.0)	54.3 ± 5.7	44–66	67.8 ± 6.8	2,376 (26.7)	27.0 ± 4.8	763 (8.6)	354 (4.0)	325 (3.7)
AGES	Cohort	2,959	158	1,154 (39.0)	76.5 ± 5.5	66–95	75.0 ± 8.8	2,595 (87.7)	27.1 ± 4.4	319 (10.8)	189 (6.39)	55 (1.9)
CHS	Cohort	3,204	764	1,242 (38.8)	72.2 ± 5.3	65–98	81.2 ± 6.0	1,678 (52.4)	26.3 ± 4.4	377 (11.8)	0	0
FHS	Cohort	4,062	310	1,771 (43.6)	64.7 ± 12.6	31–101	77.8 ± 10.6	2,001 (49.3)	27.7 ± 5.2	328 (8.07)	231 (5.7)	55 (1.4)
RS-I	Cohort	5,665	542	2,282 (40.3)	69.1 ± 9.0	55–99	77.6 ± 7.7	1,866 (32.9)	26.3 ± 3.7	567 (10.0)	632 (11.2)	156 (2.8)
WGHS	Cohort	20,836	648	0	54.1 ± 7.0	43–89	68.0 ± 8.2	5,022 (24.1)	25.9 ± 4.9	503 (2.4)	0	17 (0.1)
Prevalent AF												
		N per group										
AFNET	Cases	468	–	236 (50.4)	51.8 ± 7.2	29–74	51.3 ± 7.6	252 (53.8)	28.0 ± 4.9	36 (7.7)	6 (1.8)	14 (4.8)
KORA	Referents	438	–	219 (50.0)	56.2 ± 7.1	45–69	–	185 (42.2)	27.7 ± 4.5	37 (8.4)	6 (1.3)	13 (2.9)
AGES <sup>a</sup>	Cases	241	–	88 (55.7)	78.5 ± 5.9	67–95	80.9 ± 6.2	143 (90.5)	27.7 ± 4.4	20 (12.7)	8 (5.1)	5 (3.2)
	Referents	2,718	–	70 (36.1)	76.1 ± 5.4	66–94	80.4 ± 5.4	2,002 (78.2)	27.0 ± 4.5	269 (10.5)	122 (4.8)	27 (1.1)
CC	Cases	496	–	375 (75.6)	58.8 ± 10.7	20–84	51.7 ± 12.0	269 (54.2)	30.2 ± 6.2	28 (5.6)	0 (0)	0 (0)
	Referents	2,971	–	1,124 (37.8)	28.5 ± 22.2	0–87	–	–	–	–	–	–
HVH	Cases	95	–	28 (29.5)	59.5 ± 6.5	40–68	57.4 ± 6.4	50 (52.6)	34.1 ± 9.9	14 (14.7)	0	0
	Referents	193	–	106 (54.9)	59.5 ± 6.0	40–69	–	153 (79.3)	31.4 ± 7.2	31 (16.1)	9 (4.7)	7 (3.6)
CHS <sup>a</sup>	Cases	67	–	38 (56.7)	76.3 ± 5.8	66–90	–	35 (52.2)	26.6 ± 4.3	14 (20.9)	0	0
	Referents	3,204	–	1,242 (38.8)	72.2 ± 5.3	65–98	–	1,678 (52.4)	26.3 ± 4.4	377 (11.8)	0	0
FHS <sup>a</sup>	Cases	253	–	151 (59.7)	76.9 ± 9.9	45–97	70.9 ± 10.8	180 (71.1)	27.4 ± 4.8	41 (16.21)	60 (23.7)	57 (0.23)
	Referents	4,151	–	1,807 (43.5)	64.7 ± 12.6	31–101	–	2,036 (49.1)	27.7 ± 5.2	329 (7.9)	235 (5.7)	55 (1.32)
MGH	Cases	366	–	295 (80.6)	53.4 ± 10.5	21–77	46.1 ± 11.7	85.8 (22.7)	27.8 ± 5.0	12 (3.2)	4 (1.1)	10 (2.8)
MIGEN	Referents	911	–	485 (53.2)	47.9 ± 8.8	18–83	–	–	–	–	–	–
RS-I <sup>a</sup>	Cases	309	–	145 (46.9)	76.2 ± 8.7	56–98	–	131 (42.4)	25.9 ± 3.6	64 (20.7)	69 (22.3)	54 (17.5)
	Referents	5,665	–	2,282 (40.3)	69.1 ± 9.0	55–99	–	1,866 (32.9)	26.3 ± 3.7	567 (10.0)	632 (11.2)	156 (2.8)
SHIP	Cases	107	–	69 (64.5)	65.1 ± 11.5	21–81	–	59 (55.1)	29.6 ± 5.1	23 (21.5)	14 (13.1)	44 (41.1)
	Referents	1,816	–	906 (49.9)	50.7 ± 14.9	21–81	–	437 (24.1)	27.2 ± 4.5	131 (7.2)	54 (3.0)	157 (8.6)
Vanderbilt	Cases	1,081	–	738 (68.3)	59.5 ± 12.6	16–87	51.5 ± 14.7	625 (57.8)	30.7 ± 6.9	197 (18.2)	95 (8.8)	191 (17.6)

Cohort	Cohort type	Participants (n)	AF (n)	Males (%)	Age at DNA collection (mean $\pm$ s.d.)	Age at DNA collection (range)	Age of AF onset (mean $\pm$ s.d.)	Hypertension n (%)	Body mass index, in kg/m <sup>2</sup> (mean $\pm$ s.d.)	Diabetes n (%)	Myocardial infarction n (%)	Heart failure n (%)
	Referents	880	–	551 (62.6)	50.0 $\pm$ 17.4	18–91	–	463 (52.6)	28.0 $\pm$ 5.8	180 (20.5)	299 (34.0)	120 (13.6)

AF, atrial fibrillation.

<sup>a</sup>Studies included community-based prospectively ascertained prevalent atrial fibrillation cases. The other prevalent atrial fibrillation studies were of a case-control design.

**Table 2**

Summary of GWAS meta-analysis results with  $P < 5 \times 10^{-8}$

SNP	Locus	Closest gene	SNP location relative to closest gene	Minor/major allele	MAF (%)	Discovery			Replication			Overall		
						RR (95% CI)	Meta P value	$I^2$ (%), P value	RR (95% CI)	Meta P value	$I^2$ (%), P value	RR (95% CI)	Meta P value	$I^2$ (%), P value
rs666258	1q21	<i>KCNN3-PMVK</i>	Intronic	C/G	29.9	1.18 (1.13–1.23)	$2.0 \times 10^{-14}$	42.3, 0.04	–	–	–	–	–	–
rs3903239	1q24	<i>PRRX1</i>	46 kb upstream	G/A	44.7	1.14 (1.10–1.18)	$9.1 \times 10^{-11}$	$53.2, 6.3 \times 10^{-3}$	1.13 (1.06–1.20)	$2.0 \times 10^{-4}$	–	1.14 (1.10–1.17)	$8.4 \times 10^{-14}$	–
rs6817105	4q25	<i>PITX2</i>	150 kb upstream	C/T	13.1	1.64 (1.55–1.73)	$1.8 \times 10^{-74}$	$80.8, 1.4 \times 10^{-10}$	–	–	–	–	–	–
rs2040862	5q31	<i>WN78A</i>	Intronic	T/C	17.8	1.15 (1.09–1.21)	$3.2 \times 10^{-8}$	10, 0.34	1.04 (0.96–1.12)	$3.6 \times 10^{-1}$	–	1.12 (1.07–1.17)	$2.5 \times 10^{-7}$	–
rs3807989	7q31	<i>CAVI</i>	Intronic	A/G	40.4	0.88 (0.84–0.91)	$9.6 \times 10^{-11}$	10, 0.34	0.93 (0.88–0.97)	$2.7 \times 10^{-3}$	–	0.90 (0.87–0.92)	$3.6 \times 10^{-12}$	–
rs10821415	9q22	<i>C9orf3</i>	Intronic	A/C	42.4	1.13 (1.08–1.18)	$7.9 \times 10^{-9}$	49.5, 0.015	1.09 (1.04–1.15)	$7.2 \times 10^{-4}$	–	1.11 (1.08–1.15)	$4.2 \times 10^{-11}$	–
rs10824026	10q22	<i>SYNPO2L</i>	5 kb upstream	G/A	15.8	0.85 (0.81–0.90)	$1.7 \times 10^{-8}$	37.9, 0.06	0.91 (0.83–0.99)	$3.5 \times 10^{-2}$	–	0.87 (0.83–0.91)	$4.0 \times 10^{-9}$	–
rs1152591	14q23	<i>SYNE2</i>	Intronic	A/G	47.6	1.13 (1.09–1.18)	$6.2 \times 10^{-10}$	25.7, 0.16	1.12 (1.06–1.19)	$1.9 \times 10^{-4}$	–	1.13 (1.09–1.17)	$5.8 \times 10^{-13}$	–
rs7164883	15q24	<i>HCM4</i>	Intronic	G/A	16.0	1.16 (1.10–1.22)	$1.3 \times 10^{-8}$	0, 0.85	1.24 (1.16–1.32)	$1.3 \times 10^{-10}$	–	1.19 (1.14–1.24)	$2.8 \times 10^{-17}$	–
rs2106261	16q22	<i>ZFHX3</i>	Intronic	T/C	17.6	1.24 (1.17–1.30)	$3.2 \times 10^{-16}$	$58.8, 1.6 \times 10^{-3}$	–	–	–	–	–	–

MAF, minor allele frequency; RR, relative risk.  $I^2$  represents the proportion of variability in the effect size due to between-study variability. We did not attempt replication of the previously published genetic loci associated with atrial fibrillation on chromosomes 1q21 (*KCNN3*)<sup>2</sup>, 4q25 (*PITX2*)<sup>4</sup> and 16q22 (*ZFHX3*)<sup>3,5</sup>.